Intravenous versus oral iron supplementation for anemic patients with rectal cancer undergoing preoperative chemoradiotherapy

Not Applicable

Recruiting

Conditions: Neoplasms

Registration Number: KCT0009260

Lead Sponsor: Chonnam National University Hospital Hwasun Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 94

Inclusion Criteria

Patients with primary rectal cancer without distant metastases
- Age 20 or older
- patients who agree to participate in this study and sign the clinical trial consent form
- Iron deficiency anemia
: Hemoglobin <12g/dL for women, hemoglobin <13g/dL for men
Serum ferritin <30 ng/mL
Serum transferrin saturation (TSAT) <20%
- Patients scheduled to receive neoadjuvant chemotherapy

Exclusion Criteria

- requiring emergency surgery due to obstruction, perforation, etc.
- received a blood transfusion within 1 month of screening
- Serum ferritin >800 ng/mL
- pregnant woman
- contraindicated in the use of Perinect Injection or Ferovayl Released Tablet
- ASA score >3
- If erythropoietin stimulating agent was used within 3 months of screening
- Chronic renal disease (Glomerular filtration rate <30 ml/min/m)
- Increased serum AST (GOT) and ALT (GPT) (more than 3 times normal)
- Myelodysplastic sybdrome
- hereditary hemochromatosis
- thalassemia
- Hemolytic anemia
- History of abdominal surgery (The following do not meet the exclusion criteria: appendectomy, cholecystectomy, benign gynecological surgery – oophorectomy, cesarean section, simple hysterectomy for myoma)

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of patients with normalized serum hemoglobin

Secondary Outcome Measures

Name	Time	Method
Serum hemoglobin, iron assay (ferritin, iron, TIBC [total iron binding capacity]), time taken to normalize serum hemoglobin, blood transfusion, complications, length of stay